title: Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
abstract: A new clotting assay, Pefakit APC-R Factor V Leiden (Pentapharm Ltd., Switzerland), for the detection of an increased resistance of coagulation factor V against degradation by activated protein C, caused mainly by the factor V Leiden mutation, was evaluated in clinical studies at two University Centers in Europe and the US. The performance was compared with the performance of the routinely used predicate device COATEST APC Resistance V (Chromogenix IL, USA). Both tests were run in parallel on a STA-R analyzer (Diagnostica Stago, France). Samples from subjects undergoing routine laboratory thrombophilia screening were examined, 187 at the Institute of Medical and Chemical Laboratory Diagnostics (IMCLD), University of Vienna, Austria, and 236 at the Duke University Medical Center (DUMC), Durham/Raleigh NC, USA. All samples were analyzed for factor V Leiden mutation and prothrombin 20210 G/A mutation using standard PCR methods. The data show that the Pefakit APC-R Factor V Leiden assay discriminates very well between healthy controls and carriers of the factor V Leiden mutation, even in patients with lupus anticoagulant or with deficiency in Protein C or Protein S. Furthermore, this new test is able to discriminate well between heterozygous and homozygous carriers of the factor V Leiden mutation. In both studies the Pefakit assay showed 100% sensitivity and 100% specificity for detection of the factor V Leiden mutation, compared to 93.1% sensitivity and 93.0% specificity for the COATEST APC Resistance V in the IMCLD study and 93.9% sensitivity and 95.6% specificity in the DUMC study. The new test has PCR-like discrimination power which will help to decrease costs by reducing the need for PCR verification of borderline cases.
authors.affiliation: Research and Development Haemostasis, Pentapharm Ltd., Engelgasse 109, 4002 Basel, Switzerland. reto.schoeni@pentapharm.com
authors.forename: Reto
authors.initials: R
authors.lastname: Schöni
authors.forename: Peter
authors.initials: P
authors.lastname: Quehenberger
authors.forename: Jogin R
authors.initials: JR
authors.lastname: Wu
authors.forename: Marianne
authors.initials: M
authors.lastname: Wilmer
mesh_terms: D020016:Activated Protein C Resistance / Q000175:diagnosis*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002624:Chemistry, Clinical / Q000379:methods*; D002648:Child; D005060:Europe; D005165:Factor V / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011516:Prothrombin / Q000235:genetics; D012680:Sensitivity and Specificity; D019851:Thrombophilia / Q000209:etiology / Q000235:genetics; D014481:United States
chemical_list: C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin